Mimotopes and Genzyme Pharmaceuticals to collaborate
Friday, 27 January, 2006
PharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.
The exclusive and global agreement commences on February 1, 2006.
Mimotopes will supply customers with research grade peptides and related services up to the point of lead candidate identification in pre-clinical applications.
Genzyme Pharmaceuticals, a business unit of Genzyme Corporation that develops and manufactures peptide and lipid products, will supply customers with identified lead candidate peptides for pre-clinical applications through to clinical and therapeutic grade peptides and related services.
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
